← Back to Clinical Trials
Recruiting NCT07320157

NCT07320157 The Effect of HPV Education Provided to Women on Their Knowledge Levels, HPV Screening, and Vaccination Uptake

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07320157
Status Recruiting
Phase
Sponsor Ufuk University
Condition HPV (Human Papillomavirus)-Associated
Study Type INTERVENTIONAL
Enrollment 64 participants
Start Date 2026-01-09
Primary Completion 2026-01-23

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 35 Years
Study Type INTERVENTIONAL
Interventions
Online Education Intervention GroupContral Group

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 64 participants in total. It began in 2026-01-09 with a primary completion date of 2026-01-23.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Type of Study: This study was planned to be an observational study. Purpose of the Study: To evaluate the impact of HPV education given to women on their knowledge levels and HPV screening and vaccination.The main question\[s\] it aims to answer \[is/are\]: H1: There is a difference in the mean Human Papillomavirus (HPV) Knowledge Scale score between the intervention group women who participated in Human Papillomavirus (HPV) education and the control group women. H2: There is a difference between the intervention group women and the control group women in terms of their participation in HPV screening tests. H2: There is a difference between the intervention group women and the control group women in terms of their HPV vaccination status. Participants Participants will be assigned to a control and intervention group. Online training will be provided to the intervention group, and the results of the training will be reported.

Eligibility Criteria

Inclusion Criteria: * Being female * Women aged 18-35 years * Ability to speak and understand Turkish at a level sufficient to communicate with the researcher * Having the technical equipment necessary to participate in a video interview * No diagnosis of HPV positivity * Not having received the HPV vaccine * Not having undergone HPV DNA/Pap smear testing in the past 5 years * No diagnosis of cervical cancer * Voluntary willingness to participate in the study * No diagnosis of a psychiatric disorder Exclusion Criteria: * Being male * Having severe physical or cognitive impairments that prevent completing the questionnaire * Being under 18 years of age or over 35 years of age * Inability to speak or understand Turkish * Lack of technical equipment to participate in a video interview * Having a diagnosis of HPV positivity * Having received the HPV vaccine * Having undergone HPV DNA/Pap smear testing in the past 5 years * Having a diagnosis of cervical cancer * Having a diagnosed psychiatric disorder Not agreeing to participate in the study

Contact & Investigator

Central Contact

GİZEM B BİLMEZ GİZEM, PHD STUDENT

✉ gzm_erdogan@hotmail.com

📞 905532657387

Frequently Asked Questions

Who can join the NCT07320157 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 35 Years, studying HPV (Human Papillomavirus)-Associated. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07320157 currently recruiting?

Yes, NCT07320157 is actively recruiting participants. Contact the research team at gzm_erdogan@hotmail.com for enrollment information.

Where is the NCT07320157 trial being conducted?

This trial is being conducted at Ankara, Turkey (Türkiye).

Who is sponsoring the NCT07320157 clinical trial?

NCT07320157 is sponsored by Ufuk University. The trial plans to enroll 64 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology